Insilico medicine (“insilico”), a clinical-phase biotechnology company, which is operated by generative artificial intelligence (AI), today announces that the first patient with a global multi-layered clinical test (NCT064144460) with ISM3412 announces the first patient with a potential form, a potential form with a potential form. Tumor.
The study of phase 1 includes two parts: increase in dosage and dose selection adaptation, where participants will receive ISM3412 orally once daily, not only safety, tolerance, pharmacocyanamics/pharmacocyanamics properties and anti-tumor efficacy of ISM3412, but also to prescribe the recommended dose in further studies. To date, the test has completed the nomination for the first subject and DLT (dose-limited poisoning), which is the first dose in Cancer Hospital for Kohrurt, which is in the Academy of Medical Sciences of the leading site, medical sciences in China.
The first-in-raogi dose is an important milestone for any drug candidate, which marks its transition from pre-evaluation in the human body. We are thrilled to see ISM3412 emerging as a possible treatment option, developed with AI’s support- especially for patients with advanced or metastatic tumors, who can benefit from novels and more efficient treatment methods. ,
Feng Rain PhD, Co-CEO and CSO Insilico Medicine
ISM3412 is an orally bioable, highly selected, and powerful Mat2A (Methionin Adenocyteransferase 2A) that is empowered by the Insilico -owned generative chemistry platform, Chemistry 42. The drug targets cancer with MTAP deletion, a common genetic change found in many solid tumors, including non-six cell lung cancer (NSCLC), pancreatic cancer and bladder cancer. MTAP deletion creates a synthetic malignant vulnerability that exploits by stopping ISM3412 Mat2A, reduces the levels of S-conosylmethionine (sam)-selectively kills MTAP cancer cells, sparling the molecules and healthy cells required for cell functions.
Directed by Synthetic Lethhality Strategy, ISM3412 was designed using the ligand-based A-able drug design by Insilico’s Generative Chemistry Application, Chemistry 42, and nominated as a chronic candidate compound in May 2022. In pregnant studies. The relevant data is presented as an abstract and poster at the annual meeting of AACR (American Association for Cancer Research) on 2023. In April and May 2024, ISM3412 obtained IND withdrawal from US FDA and NMPA, paving the way for future clinical studies.
“In pregnant studies, ISM3412 has demonstrated a promising protection profile, which highlights its ability to improve treatment options for patients. Efficacy In the form of a monotherapy, ISM3412 demonstrated cohesive effects on being combined with chemotherapy and Prmot5 inhibitors. We are ready to validate these results in our ongoing phase 1 study in patients. “MD Sujata Rao, Chief Medical Officer of Insilico Medicine, said.
By integrating advanced AI and automation technologies, Insilico Medicine has demonstrated improving significant efficiency in practical applications, installing a benchmark for AI-operated pharmaceutical research and development. Compared to traditional medicine, compared to the required 2.5-4 years, 22 enrolled candidates of INSILICO took only 12-18 months from 2021 to 2024, which requires average of only 60-200 molecules, for the enrollment of Preclinical Candidates (PCCS), for the progress for progress for progress for progress from project initiation. The success rate from PCC to Ind-enabling phase reached 100%.
